Concurrent versus Sequential Sorafenib Therapy in Combination with Radiation for Hepatocellular Carcinoma

Sorafenib (SOR) is the only systemic agent known to improve survival for hepatocellular carcinoma (HCC). However, SOR prolongs survival by less than 3 months and does not alter symptomatic progression. To improve outcomes, several phase I-II trials are currently examining SOR with radiation (RT) for...

Descripción completa

Detalles Bibliográficos
Autores principales: Wild, Aaron T., Gandhi, Nishant, Chettiar, Sivarajan T., Aziz, Khaled, Gajula, Rajendra P., Williams, Russell D., Kumar, Rachit, Taparra, Kekoa, Zeng, Jing, Cades, Jessica A., Velarde, Esteban, Menon, Siddharth, Geschwind, Jean F., Cosgrove, David, Pawlik, Timothy M., Maitra, Anirban, Wong, John, Hales, Russell K., Torbenson, Michael S., Herman, Joseph M., Tran, Phuoc T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675179/
https://www.ncbi.nlm.nih.gov/pubmed/23762417
http://dx.doi.org/10.1371/journal.pone.0065726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675179/
https://www.ncbi.nlm.nih.gov/pubmed/23762417
http://dx.doi.org/10.1371/journal.pone.0065726

Ejemplares similares